Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma

Cholangiocarcinoma (CCA) is a rare and aggressive type of malignant tumor. In the past few years, there has been an increase in the incidence of CCA. Surgery is the only effective treatment but is only suitable for a small percentage of patients. Comprehensive treatment is the normal therapy for ter...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1142690
Main Authors Du, Jiajia, Lv, Xing, Zhang, Zunyi, Huang, Zhiyong, Zhang, Erlei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 01.03.2023
Subjects
Bile Duct Neoplasms - genetics
Bile Ducts, Intrahepatic - pathology
cholangiocarcinoma
Cholangiocarcinoma - drug therapy
Humans
Immunology
Immunotherapy
PD-1
Receptors, Fibroblast Growth Factor
systemic therapy
targeted therapy
targeted therapy
systemic therapy
PD-1
cholangiocarcinoma
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Cholangiocarcinoma (CCA) is a rare and aggressive type of malignant tumor. In the past few years, there has been an increase in the incidence of CCA. Surgery is the only effective treatment but is only suitable for a small percentage of patients. Comprehensive treatment is the normal therapy for terminal CCA patients, depending basically on gemcitabine and cisplatin combination chemotherapy. In the past decade, the emergence of next-generation sequencing technology can be used for the identification of important molecular features of CCA, and several studies have demonstrated that different CCA subtypes have unique genetic aberrations. Targeting fibroblast growth factor receptor (FGFR), isocitrate dehydrogenase (IDH) and epidermal growth factor receptor 2 (EGFR2) are emerging targeted therapies. In addition, researches have indicated that immunotherapy has a key function in CCA. There is ongoing research on programmed cell death protein 1 inhibitors (PD-1), chimeric antigen receptor T cells (CAR-T) and tumor-infiltrating leukocyte (TILs). Researches have shown that targeted therapy, immunotherapy, and conventional chemotherapy in CCA had certain mechanistic links, and the combination of those can greatly improve the prognosis of advanced CCA patients. This study aimed to review the research progress of targeted therapy and immunotherapy for CCA.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Jiang Chen, Zhejiang University, China
Reviewed by: Anuhya Kommalapati, Mayo Clinic, United States; Lingxi Jiang, Shanghai Jiao Tong University, China
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1142690